Clinical Trials in Atlanta, Georgia
26 recruiting
Showing 1–20 of 88 trials
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast CarcinomaColorectal CarcinomaMelanoma+2 more
Wake Forest University Health Sciences2,000 enrolled467 locationsNCT06418204
Recruiting
Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled531 locationsNCT06058377
Recruiting
National Cancer Institute "Cancer Moonshot Biobank"
Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more
National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401
Recruiting
Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
AstraZeneca675 enrolled281 locationsNCT06357533
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 2
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Ductal Carcinoma in Situ
QuantumLeap Healthcare Collaborative400 enrolled27 locationsNCT06075953
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Solid Tumor
Eisai Inc.182 enrolled58 locationsNCT04300556
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company1,264 enrolled424 locationsNCT06119581
Recruiting
Phase 1
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Advanced Breast Cancer
Stemline Therapeutics, Inc.240 enrolled30 locationsNCT06638307
Recruiting
Phase 1Phase 2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Breast Cancer
Genentech, Inc.285 enrolled21 locationsNCT07100106
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled293 locationsNCT06926868
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Phase 1
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Breast NeoplasmsColorectal NeoplasmsProstate Neoplasm+2 more
Eli Lilly and Company421 enrolled25 locationsNCT07114601
Recruiting
Phase 1
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Breast CancerEndometrial CancerAdvanced Solid Tumor+2 more
Alterome Therapeutics, Inc.110 enrolled51 locationsNCT06533059
Recruiting
Phase 1Phase 2
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Metastatic Breast CancerHER2-negative Breast CancerAdvanced Breast Cancer+1 more
RayzeBio, Inc.124 enrolled31 locationsNCT06590857
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
Breast CancerDepression
NRG Oncology402 enrolled277 locationsNCT06748222
Recruiting
Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,295 enrolled829 locationsNCT05812807